Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Explosive Bidding Situation Setting Up For Amarin

|Includes:Amarin Corporation PLC (AMRN), AZN, GSK, PFE, TEVA

Several recent developments flying under the radar right now:

The patent appeal that is unfavorable to GSK presents three major strategic plays to acquire Amarin (NASDAQ:AMRN):

1. GSK main player - in order to defend against Lovaza revenue loss from potential future generics

2. AZN back in as a suitor - in order to maintain a player in the Omega-3 space --the Lovaza generic ruling cancels out Omthera completely

3. Teva now makes more sense - in order to lock up the Omega-3 drug class and price protect against other generic plays

Also, AMRN has named Lipator as the stain agent to be patented with Vascepa. That means PFE prime suitor as well.

I will reiterate my stand on NCE success, Anchor approval in December and a $28-32 short term (within 12-mo) price target.